These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35590156)

  • 1. Hutchinson-Gilford Progeria paves the way for novel targeted anti-aging therapies.
    Dreesen O; Kennedy B
    Med; 2021 Apr; 2(4):353-354. PubMed ID: 35590156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
    Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
    J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
    Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of Farnesylated Progerin in Hutchinson-Gilford Progeria Patient Cells by Mass Spectrometry.
    Camafeita E; Jorge I; Rivera-Torres J; Andrés V; Vázquez J
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
    Arnold R; Vehns E; Randl H; Djabali K
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
    Wang Y; Ostlund C; Worman HJ
    Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
    Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
    Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW; Glover TW
    Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
    Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
    Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
    Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
    Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
    Yang SH; Chang SY; Ren S; Wang Y; Andres DA; Spielmann HP; Fong LG; Young SG
    Hum Mol Genet; 2011 Feb; 20(3):436-44. PubMed ID: 21088111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
    Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
    Finley J
    Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele.
    Yang SH; Qiao X; Farber E; Chang SY; Fong LG; Young SG
    J Biol Chem; 2008 Mar; 283(11):7094-9. PubMed ID: 18178963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
    Gordon LB; Kleinman ME; Miller DT; Neuberg DS; Giobbie-Hurder A; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland R; Snyder BD; Fligor B; Bishop WR; Statkevich P; Regen A; Sonis A; Riley S; Ploski C; Correia A; Quinn N; Ullrich NJ; Nazarian A; Liang MG; Huh SY; Schwartzman A; Kieran MW
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16666-71. PubMed ID: 23012407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
    McClintock D; Gordon LB; Djabali K
    Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
    Yang SH; Qiao X; Fong LG; Young SG
    Biochim Biophys Acta; 2008; 1781(1-2):36-9. PubMed ID: 18082640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach.
    Rajeev M; Ratan C; Krishnan K; Vijayan M
    Recent Pat Biotechnol; 2021; 15(4):266-285. PubMed ID: 34602042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibition in HGPS.
    Misteli T
    Cell; 2021 Jan; 184(2):293. PubMed ID: 33482093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
    Gordon LB; Shappell H; Massaro J; D'Agostino RB; Brazier J; Campbell SE; Kleinman ME; Kieran MW
    JAMA; 2018 Apr; 319(16):1687-1695. PubMed ID: 29710166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.